Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX). This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results